||5R01CA138580-03 Interpret this number
||Brigham And Women'S Hospital
||Growth Hormones and Breast Cancer Risk
The relationship between growth factors and breast cancer etiology is complex and not completely understood;
however, strong experimental evidence supports their role in breast carcinogenesis. Therefore, in this
proposal, we will conduct a detailed evaluation of prolactin and its association with breast cancer risk. This
study will use a prospective nested case-control design among pre- or perimenopausal women at blood
collection (1,542 cases diagnosed through 2011). Samples were collected in the Nurses' Health Study II
(NHSII) in 1996-99 from 29,611 women, ages 32 to 52 years, and in 1989-90 from 32,826 NHS participants,
ages 43 to 62 years. In addition to assessing the overall prolactin-breast cancer association, this study will
examine whether prolactin is more strongly associated with risk of estrogen receptor positive tumors, as well
as tumors staining positive for prolactin, prolactin receptor, cyclin D1, and phosphorylated STAT3 and STAT5.
Observing such specificity to the prolactin receptor and its downstream targets would add substantially to the
case for causality. Prior studies have assessed prolactin levels using an immunoassay that measures multiple
isoforms with differing biologic activities. This study will provide the first prospective assessment of breast
cancer risk with a prolactin bioactivity assay, which may better reflect the portion of prolactin that is biologically
important. Also, since few correlates of bioactive prolactin are known, this proposal will assess, for the first
time, its relationship with known and putative breast cancer risk factors (e.g., parity, shift work). The availability
of existing hormone data for this cohort will enable the examination of prolactin as an independent breast
cancer risk factor and its interrelationships with other hormones. Importantly, we have added an aim to directly
evaluate the addition of prolactin to a comprehensive risk prediction model for breast cancer, which could be
useful clinically. Several features of prolactin make it an attractive candidate for inclusion into such models,
including that the immunoassay is a standardized and common clinical assay that is very inexpensive and easy
to measure. Further, the magnitude of the prolactin association appears to be similar to other factors included
in breast cancer risk prediction models. We also will evaluate the inclusion of the bioassay; if this improves
prediction better than the immunoassay, it would provide impetus to identify the specific isoforms of prolactin
that increase risk of breast cancer and develop inexpensive assays for their measurement. Other grants will
provide funding for follow-up and other hormone assays, increasing the cost-effectiveness of this project.
Ultimately, elucidating the role of prolactin in breast cancer could open up multiple new areas of research for
both treatment and prevention.
A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development.
Tworoger SS, Eliassen AH, Zhang X, Qian J, Sluss PM, Rosner BA, Hankinson SE
Cancer Res, 2013 Aug 1;73(15), p. 4810-9.
2013 Jun 19.
Insulin-like growth factor-1, insulin-like growth factor-binding protein-3, growth hormone, and mammographic density in the Nurses' Health Studies.
Rice MS, Tworoger SS, Rosner BA, Pollak MN, Hankinson SE, Tamimi RM
Breast Cancer Res Treat, 2012 Dec;136(3), p. 805-12.
2012 Oct 21.